Agile Therapeutics, Inc. (AGRX) Latest Broker Coverage
A number of investment brokers have recently updated their price targets on shares of Agile Therapeutics, Inc. (AGRX). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.
Most recent broker ratings
02/02/2016 – Agile Therapeutics, Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 15 price target on the stock.
01/08/2016 – Cantor Fitzgerald began new coverage on Agile Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 18 price target on the stock.
12/29/2015 – Noble Financial began new coverage on Agile Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 16 price target on the stock.
11/10/2015 – Agile Therapeutics, Inc. had its “outperform” rating reiterated by analysts at William Blair. They now have a USD 18 price target on the stock.
04/02/2015 – FBR Capital Markets began new coverage on Agile Therapeutics, Inc. giving the company a “outperform” rating. They now have a USD 17 price target on the stock.
12/30/2014 – Sterne Agee began new coverage on Agile Therapeutics, Inc. giving the company a “buy” rating.
09/16/2014 – Agile Therapeutics, Inc. had its “buy” rating reiterated by analysts at Janney Montgomery Scott. They now have a USD 18 price target on the stock.
The share price of Agile Therapeutics, Inc. (AGRX) was up +1.21% during the last day of trading, with a day high of 6.04. 42666 shares were traded during the last session.
The stock’s 50 day moving average is 6.10 and its 200 day moving average is 6.98. The stock’s market capitalization is 130.85M. Agile Therapeutics, Inc. has a 52-week low of 5.32 and a 52-week high of 12.15.
View other investors thoughts on Agile Therapeutics, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.